A novel derivative of the fungal antimicrobial peptide plectasin is active against *Mycobacterium tuberculosis*

Erik Tenland\textsuperscript{a}, Nitya Krishnan\textsuperscript{b}, Anna Rönnholm\textsuperscript{a}, Sadaf Kalsum\textsuperscript{c}, Manoj Puthia\textsuperscript{d}, Matthias Mörgelin\textsuperscript{e}, Mina Davoudid\textsuperscript{c}, Magdalena Otrocka\textsuperscript{f}, Nader Alaridah\textsuperscript{a}, Izabela Glegola-Madejska\textsuperscript{b}, Erik Sturegård\textsuperscript{g}, Artur Schmidtchen\textsuperscript{d}, Maria Lerm\textsuperscript{c}, Brian D. Robertson\textsuperscript{b}, Gabriela Godaly\textsuperscript{a,∗}

\textsuperscript{a} Department of Microbiology, Immunology and Glycobiology, Institution of Laboratory Medicine, Lund University, Lund, Sweden
\textsuperscript{b} MRC Centre for Molecular Bacteriology and Infection, Department of Medicine, Imperial College London, UK
\textsuperscript{c} Department of Clinical and Experimental Medicine, Faculty Medicine and Health Sciences, Linköping, Sweden
\textsuperscript{d} Department of Dermatology and Venereology, Institution of Clinical Sciences, Lund University, Lund, Sweden
\textsuperscript{e} Colzyx AB, Medicon Village, Lund, Sweden
\textsuperscript{f} Chemical Biology Consortium Sweden, Science for Life Laboratory, Karolinska Institute, Stockholm, Sweden
\textsuperscript{g} Department of Clinical Microbiology, Institution of Translational Medicine, Lund University, Malmö, Sweden

\textbf{ARTICLE INFO}

\textbf{Keywords:}
Mycobacterium tuberculosis
Antimicrobial peptides
Tuberculosis treatment

\textbf{ABSTRACT}

Tuberculosis has been reaffirmed as the infectious disease causing most deaths in the world. Co-infection with HIV and the increase in multi-drug resistant *Mycobacterium tuberculosis* strains complicates treatment and increases mortality rates, making the development of new drugs an urgent priority. In this study we have identified a promising candidate by screening antimicrobial peptides for their capacity to inhibit mycobacterial growth. This non-toxic peptide, NZX, is capable of inhibiting both clinical strains of *M. tuberculosis* and an MDR strain at therapeutic concentrations. The therapeutic potential of NZX is further supported in vivo where NZX significantly lowered the bacterial load with only five days of treatment, comparable to rifampicin treatment over the same period. NZX possesses intracellular inhibitory capacity and co-localizes with intracellular bacteria in infected murine lungs. In conclusion, the data presented strongly supports the therapeutic potential of NZX in future anti-TB treatment.

\section{1. Introduction}

Despite the availability of antibiotics and the extensive use of the live-attenuated vaccine Bacille Calmette-Guérin (BCG), tuberculosis (TB) remains a major health concern with an estimated 10.4 million new cases every year. Current treatment and vaccination programmes have failed to make a significant impact on either transmission or protection against disease, while co-infection with HIV and the emergence of drug resistant strains has further undermined TB control programmes [1,2]. Isoniazid and Rifampicin form an essential part of the standard four-drug treatment for drug-sensitive infections, with a cure rate of 95% under optimal conditions [3]. However, the duration of treatment is long, varying from six months for drug susceptible TB, to more than two years for multi-drug resistant (MDR) TB, where bacteria are resistant to the first-line anti-TB drugs, and extensively drug resistant (XDR) TB in which strains have acquired additional resistance to fluoroquinolone and any one of the three injectable second-line anti-TB drugs [4]. Prolonged treatment contributes to poor patient compliance and the emergence of antibiotic resistance. In 2016, the WHO estimated 600,000 new cases of MDR-TB, of which 6.2% were XDR-TB [5,6].

Antimicrobial peptides (AMPs) have gained interest as potential therapeutic tools to treat mycobacterial infections. Among the antimicrobial peptides, human defensins and cathelicidins play an important role linking innate and adaptive immune responses [7]. Defensins are a family of naturally occurring cysteine-rich peptides found in higher plants and animals that display activity against a wide variety of microbes, making them attractive drug candidates. The majority of defensins act through disruption of microbial membranes, although they may have additional host-related immune-modulating activities [8]. Most defensins are amphipathic molecules with clusters of positively charged and hydrophobic amino-acid side chains that interact with microbial membranes. It has been proposed that the cationic portion targets the
peptide to the negatively charged bacterial membrane, while the hydrophobic portion intercalates into the membrane [9,10].

Many naturally occurring AMPs have been tested for activity against *Mycopoccus tuberculosis*, including human and rabbit defensins and porcine protegrins [11–14]. In addition to naturally occurring AMPs, synthetic libraries have been tested for activity against *M. tuberculosis* [15]. Suboptimal efficacy, instability and/or toxicity have so far precluded testing of most AMPs in animal models of *M. tuberculosis* infection. Until now, only the peptides LL-37, innate defense regulators and ecumicin showed significant results in experimental TB murine models after 25–28-days of treatment [16,17]. In this study we investigated NZX, a novel derivative of plectasin, which is the first fungal defensin-like AMP with proven activity against *M. tuberculosis* in vitro and in a murine model of acute *M. tuberculosis* infection. We found NZX is proteolytically stable and non-toxic to eukaryotic cells but kills *M. tuberculosis* at concentrations comparable to conventional antibiotics in both *in vitro* and *in vivo* models. In the murine TB-model, we found that NZX associated with mycobacteria inside macrophages, and substantially lowered the bacterial load with five days of treatment, comparable to the reduction seen with rifampicin treatment over the same time period.

2. Materials and methods

2.1. Peptides

Four of the investigated peptides were previously reported to possess activity against *M. tuberculosis in vitro* or *in vivo* (Table 1). LL-37 and the synthetic variants of tryptophan-rich peptides were previously shown to eliminate *M. tuberculosis* at low concentrations in *in vitro* [14,16,20,21]. Plectasin as a potential TB therapeutic although mentioned in the literature has not been tested experimentally to-date [22,23].

NZ2114 is a variant of plectasin, originally isolated from *Pseudoplectania nigrella* [18,24,25]. Numerous publications report NZ2114 to exhibit improved activity compared to plectasin against *staphylococcus*, including *Staphylococcus aureus*, as well as *Streptococcus pneumoniae* [18,24,25] (Table 1). The peptide NZX was manufactured by solid phase peptide synthesis, followed by cyclisation of the naturally occurring disulphide bonds and purification by sequential chromatography steps (PolyPeptide Laboratories AB, Limhamn, Sweden). The peptide NZ2114 was provided by Adenium ApS, Denmark. It is very pure (97.3%) of the peptides was confirmed by high-performance liquid chromatography. Table 1 Screening of peptides against mycobacteria.

| Name | Peptide |
|------|---------|
| LL-37 | LGDFRFKSSKGIKGEKRIVQKDFLRLNVPRTES-NH₂ |
|       | WKKLEWIK-ÖHtFA |
|       | WKKLEWIKG-NH₂tFA |
|       | WKKLEWIKG-NH₂tHOac |
| NZ2114 | GFGCGNPWNEGDRLCGNHCKSIEVGKKGCAKGGFVCCKY |
| NZX | GFGCGNPWNEGDRLCGNHCKSIEVGKKGCAKGGFVCCKY |

* Disulphide bonds at position C4-C30, C15-C37, C19-C39 and differences in amino acid sequence N95, L131, K32R (bold).

bovis calmette-guerin (BCG) Montreal containing the pSTM1-luxAB plasmid was prepared as previously described [26]. Briefly, BCG was grown in Middlebrook 7H9 broth, supplemented with 10% ADC enrichment (Middlebrook Albumin Dextrose Catalase Supplement, Becton Dickinson, Oxford, UK) and hygromycin (50 μg/ml; Roche, Lewes, UK), the culture was washed twice with sterile PBS, and re-suspended in broth and then dispensed into vials. Glycerol was added to a final concentration of 25% and the vials were frozen at −80°C. Prior to each experiment, a vial was defrosted, added to 9 ml of 7H9/ADC/hygromycin medium, and incubated with shaking for 72 h at 37°C. Mycobacteria were then centrifuged for 10 min at 3000×g, washed twice with PBS, and re-suspended in 10 ml of PBS.

For murine TB experiments, we used *M. tuberculosis* H37Rv with known expression of the surface lipid phenicol dimycocerosate (PDIM) (a kind gift from Christophe Guihot, Institut de Pharmacologie et de Biologie Structurale (IPBS), Toulouse, France). The strain was cultured to mid-log phase in Middlebrook 7H9 culture medium, supplemented with 0.05% Tween 80, 0.2% glycerol and 10% oleic acid-albumin-dextrose-catalase (OADC) enrichment (Becton Dickinson, Oxford, UK).

In preparation for MIC-determination and electron microscopy studies of the effect of NZX on *M. tuberculosis in vitro*, H37Rv (ATCC 27294) and three clinical strains isolated from pleural effusions (TB2016/268 (clinical isolate 1), TB1298 (clinical isolate 2) and TB4001 (clinical MDR isolate)) were cultured in MGIT960 according to manufacturer's instructions. TB4001 is an MDR-TB strain, resistant to Rifampicin and Isoniazid (Supplementary Table 2). The other two strains were fully susceptible to first-line antibiotics and were verified to be *M. tuberculosis* using standard methods at Clinical Microbiology, Regional Laboratories Skåne, Lund, Sweden (data not shown). *Mycobacterium smegmatis mec155 (a kind gift from Prof. Leif Kisseborn, Department of Cell and Molecular Biology, Box 596, Biomedical Centre, Uppsala, Sweden).

For the intracellular experiment, *M. tuberculosis* H37Rv (ATCC 27294) transformed with a Live-Dead reporter plasmid [27] was used for infecting primary human macrophages. The bacteria were grown to mid-log phase at 37°C in Middlebrook 7H9 medium (BD Biosciences, San Diego, CA, USA) with 0.05% Tween-80, 0.05% glycerol and albumin-dextrose-catalase enrichment (ADC, Becton Dickinson) in the presence of 50 μg/ml hygromycin B (Sigma-Aldrich, St Louis, MO) as a selective antibiotic. The bacteria were passaged at 1:9 in the medium and incubated for one more week before use in experiments.

2.3. Cells

Human venous blood mononuclear cells were obtained from healthy volunteers using a Lymphoprep density gradient (Axis-Shield, Oslo, Norway) according to the manufacturer's instructions. To obtain pure monocytes, CD14 micro beads were applied to the cell suspension, washed and passed through a LS-column according to manufacturer’s description (130-050-201, 130-042-401, Miltenyi Biotech, USA). The monocytes were counted (Sysmex), diluted in RPMI 1640 supplemented with 5% FCS, NEAA, 1 mM Sodium Pyruvate, 0.1 mg/ml Genticin (11140-035, 111360-039, 15710-49, Gibco, Life Technologies) and 50 μg/ml GM-CSF (215-GM, R&D systems) and seeded in 96-well plates (10⁵/well) for a week to differentiate into macrophages. Infection experiments were performed in RPMI 1640 without Genticin.

The human monocyte cell line, THP-1-XBlue™-CD14 (Invirogen, San Diego, CA, USA) were cultured in RPMI 1640 supplemented with 10% FCS, Antibiotic-Antimycotic, Zeocin, and Geneticin (15240062, R25005, 10131035, Gibco, Life Technologies).

2.4. Screening studies

To measure peptide activity against mycobacteria, BCG expressing luxAB was diluted in Middlebrook 7H9 medium (10⁴ CFU; 150 μl/well)
in 96-well opaque white plates (Corning). Peptides (0, 6.3, 12.5, 25, 50 or 100 μM) were added to the wells. Growth controls containing no peptide and peptide without bacteria were also prepared. The plates were incubated at 37 °C for 24 h before adding 0.1% n-decyl aldehyde (Decanal, Sigma), a substrate for bacterial luciferase. Bioluminescence was measured as relative luminescence unit (RLU) for 1 s using a TriStar® microplate reader (Berthold Technologies). The results are representative of two biological repeats.

2.9. Intracellular MIC

Infection of primary human macrophages was done with a protocol modified from a previously described method [29,30]. Briefly, macrophages and M. tuberculosis H37Rv strain expressing m-Cherry [27] were mixed in a tube at a multiplicity of infection (MOI) of 1:1 and seeded in 384-well plates. Isoniazid at a concentration of 0.1 mg/ml (0.7 μM) was used as a positive control. After 6 days of incubation, the infected cells were fixed with paraformaldehyde, stained with nuclear stain DAPI and analysed using ImageXpress (Molecular Devices). Bacterial numbers were estimated by enumerating the particles with red fluorescence in the obtained images.

2.10. Marine treatment model

All animal procedures were performed under the license issued by the UK Home Office and in accordance with the Animal Scientific Procedures Act of 1986. Six to eight-week-old female BALB/c mice (Charles River Ltd, UK) were maintained in biosafety containment level 3 (BSL3) facilities at Imperial College London, London, United Kingdom according to institutional protocols [31]. Mice were infected with 7 × 10^3 CFU/ml of M. tuberculosis H37Rv via the intranasal route (control group (n = 15, plus 3 mice to check bacterial numbers implanted in the lungs on day 2), NZX group (n = 5) and rifampicin group (n = 5). The experiment was repeated twice. Two days after infection, 3 control mice were euthanized to determine the actual dose implanted in the lungs. Five mice from the control group were euthanized prior to the start of treatment in order to determine the bacterial load in the lungs. Following 19 days of infection, the NZX groups were treated for five consecutive days with 0.83 mg NZX (33 mg/kg) diluted in 50 μl PBS by intra-tracheal administration. The control group received 50 μl PBS by the same route. As an additional treatment control, five mice were dosed intra-tracheally with rifampicin at a concentration of 20 mg/kg for 5 days. An additional group of mice (n = 5) was treated with gold-labelled NZX. Following treatment, mice were culled and the lungs were aseptically removed. The left lobe of the lung was placed in 10% buffered formalin for 24 h, for histology. The remaining tissue were homogenized in PBS containing 0.05% Tween-80, serially diluted and plated on Middlebrook 7H11 agar plates supplemented with 0.5% glycerol and 10% OADC. The number of CFU from all mice was enumerated 21 days later.

2.11. Histology and immunohistochemistry

Formalin fixed tissue was transferred to 70% ethanol overnight, then embedded and frozen in optimal cutting temperature compound (Sakura Finetek USA) for cryosectioning (8 μm; Leica microtome). Sections were collected on positively charged microscope slides (Super Frost/Plus, Thermo Fisher Scientific), fixed in acetone-methanol (1:1, 10 min), dried, permeabilized (0.2% Triton X-100, 5% normal goat serum/PBS), and stained with primary rat anti-neutrophil antibody (NIMP-R14) (1:200; Abcam, ab25577), rabbit monoclonal anti-M. tuberculosis antibody (1:100; Loxen, NB200-579) and mouse anti-neutrophil (1:50; Abcam, ab119352), followed by Alexa Fluor 488 (1:50; Immunoire, 568–labelled rabbit anti-rat or goat anti-mouse immunoglobulin G secondaries (Molecular Probes; A-21210, A-11001, and A-11011). Nuclei were counterstained with DAPI (4′,6-diamidino-2-phenylindole) (0.05 mM; Sigma-Aldrich). Slides were examined by fluorescence microscopy (Axiol, Olympus Optical). Richard-Allan Scientific Signature Series Hematoxylin 7211 and Eosin-Y 7111 (Thermo Scientific) were used to counterstain the tissue sections.
2.12. Transmission electron microscopy

Lung samples from infected mice treated with gold-labelled NZX and gold treated controls were embedded in Epon 812 resin according to routine protocols [32]. Specimens were observed in a Philips/FEI CM100 transmission electron microscope (Philips, Eindhoven, Holland) operated at 80 kV accelerating voltage, and images were recorded with a side-mounted Olympus Veleta camera (Olympus, Münster, Germany) with a resolution of 2048×2048 pixels.

2.13. Statistical analysis

Graphs and statistics were generated using the Prism software (version 6.1). Significance, where indicated, was calculated using the unpaired Student’s t-test or ANOVA. For the bacterial growth inhibition screening tests, ANOVA followed by Dunnett’s multiple comparison between NZX and the other peptides were performed. For the murine experiments based on two groups, untreated and treated, we analysed first the results for normal distribution (Shapiro-Wilk test) and then performed Student’s t-test as recommended by Festing et al. and Morgan et al., [33,34]. For the murine experiment comparing three groups, untreated and treated with NZX or rifampicin, we performed ANOVA followed by Dunnett’s multiple comparison and Mann-Whitney between groups. Significance was accepted at *p < 0.05, **p < 0.01, or ***p < 0.001.

2.14. Study approval

The animal studies have been approved (PPL 70/7160 and 70/8653) by the Local Animal Welfare and Ethical Review Board (London, UK). The Local Ethical Review Board Dnr 2011/403 and 2014/35 approved the donation of blood from human volunteers for the in vitro studies (Lund, Sweden), and the Lund district court approved the control animal studies (Dnr M 7–15). The blood for monocyte isolation for the toxicity analysis was donated by healthy volunteers (Local Ethical Review Board Dnr 2011/403 and 2014/35). No personal data was collected from the volunteers and the blood was pooled for the isolation of the monocytes. For the intracellular assays, human donor blood was purchased from the blood bank of Linköping University hospitals and blood donors gave written informed consent for research use of the blood.
3. Results

3.1. NZX demonstrates anti-mycobacterial activity

We investigated six peptides (Table 1) of which four were previously reported to possess activity against *M. tuberculosis* in vitro or in vivo \[^{16}\] We evaluated peptide toxicity against primary human macrophages (Fig. 1A) and peptide dose response curves against BCG (Fig. 1B). Of the peptides tested, LL-37 is the best-known antimicrobial compound and was used as a benchmark for the other peptides. At the lowest concentration tested (6.3 μM) LL-37 inhibited up to 9.7% of mycobacteria growth (Fig. 1B) but was toxic at higher concentrations (Fig. 1A).

The peptide WKWLKKWIKG, previously shown to kill mycobacteria \[^{14}\], was tested in three different versions (Table 1). Of these, WKWLKKWIKG-NH2xHOAc showed the best activity. At a concentration of 6.3 μM, this peptide inhibited 19.2% of the mycobacterial growth, showing dose-dependent inhibition (Fig. 1B). The toxicity analysis revealed that peptide version WKWLKKWIKG-OHxTFA was least toxic to primary macrophages, but bacterial killing capacity was overall lower than that of WKWLKKWIKG-NH2xHOAc. The peptides WKWLKKWIKG-NH2xHOAc and WKWLKKWIKG-NH2xTFA showed dose-dependent toxicity to macrophages, similar to LL-37 (Fig. 1B) but was toxic at higher concentrations (Fig. 1A).

The best antimicrobial activity was obtained with the plectasin derivatives NZ2114 and NZX, which both possessed high mycobacterial inhibitory capacity after 24h of incubation (Fig. 1B). Further, the toxicity analysis revealed that NZX was less toxic to human cells than LL-37 or the W-rich peptides (Fig. 1A). Comparing the two plectasin derivatives, NZX was the most effective as this peptide inhibited up to 74% of the mycobacterial growth at a concentration of 6.3 μM (Fig. 1B).

3.2. NZX inhibits *M. tuberculosis*

*M. tuberculosis* H37Rv and three clinical isolates were treated with NZX. The median 99% MIC concentrations were 6.3 μM for H37Rv, 6.3 μM and 3.2 μM for two clinical *M. tuberculosis* isolates (clinical isolate 1 and 2) and 6.3 μM for the clinical MDR isolate (Table 2). The MIC concentrations for BCG and *M. smegmatis* were also 6.3 μM. The potency of NZX compared to front-line drugs, ethambutol, rifampicin and isoniazid are shown in Supplementary Table 1. The time kill assay revealed that a single dose of NZX at 1.6 or 3.2 μM killed BCG at days eleven and eight respectively (Fig. 2A). This assay also indicated that low doses of NZX could kill BCG. The influence of NZX on mycobacterial growth was further analysed by growth kinetics of NZX treated *M. tuberculosis* H37Rv (Fig. 2B). NZX treatment induced concentration-dependent reduction of initial bacterial growth.

3.3. NZX is not toxic to human cells

As several AMPs have been reported as toxic in vitro \[^{35}\], we further investigated if NZX showed cytotoxic effects on human cells. No toxicity was detected for NZX concentrations up to 100 μM in any of the three assays (Fig. 3A–C). In addition, analysis of NF-κB activation after exposure of a monocyte cell line to NZX, revealed that the peptide does not induce inflammation (Fig. 3D).

3.4. NZX is resistant to degradation by proteases

A major barrier limiting the clinical application of AMPs is their susceptibility to degradation in biological fluids, by proteases such as the neutrophil elastase \[^{36}\]. To investigate NZX stability, the peptide was incubated with human neutrophil elastase (HNE), cathepsin G and human α-thrombin. Of the investigated proteases, only HNE at a concentration of 20 μg/ml degraded the NZX peptide, with approximately 33% breakdown after 6 h (Fig. 3E).

3.5. NZX induces intracellular killing of virulent *M. tuberculosis*

Intracellular anti-mycobacterial capacity of NZX was determined after 6 days using primary human macrophages infected with *M.
**3.6. NZX treatment efficacy in the M. tuberculosis mouse infection model**

Bactericidal activity experiments were performed in a murine TB model with *M. tuberculosis* H37Rv and repeated two times [31] (Fig. 5A and B). The mean bacterial implantation dose in the lungs, measured two days after infection, was 677 CFU/ml, and the animals received five doses of NZX or rifampicin through intra-tracheal administration. In both experiments, we observed an CFU reduction by 46% after five days (Fig. 5A, p = 0.0079) in the lungs of mice treated with NZX compared to the control animals. Comparing the untreated group with NZX group or rifampicin group, we found significant differences (p < 0.001). Both rifampicin and NZX were significantly lower compared to untreated control (p = 0.0079 in both), and we found no significant difference between rifampicin and NZX treatment (p = 0.0556).

**3.7. NZX preserves alveolar structure during acute tuberculosis**

NZX treatment abrogated tissue destruction in infected mice as shown by immunohistochemistry (Fig. 5C). Lung tissue sections from NZX-treated *M. tuberculosis*-infected mice showed less tissue damage, with lower bacterial and neutrophil counts than infected controls. Reduced inflammation and preserved alveolar structure was further confirmed by hematoxylin and eosin staining, which showed cellular infiltrates and consolidation of the lung in infected but untreated lungs, both of which were absent in the lungs of NZX-treated animals (Fig. 5C).
4. Discussion

The present study has identified a non-human peptide, NZX, that inhibits \textit{M. tuberculosis} in vitro at concentrations comparable to standard anti-mycobacterial drugs [37]. Our murine TB model supports these observations, indicating that NZX may be useful as an adjunct therapy to treat TB. Of the peptides investigated, NZX had highest capacity to inhibit mycobacterial growth at a low concentration and was found to be non-toxic even at high concentrations. Our study challenge though previous publications on LL-37 and the synthetic variants of tryptophan-rich peptides that were all reported to effectively eliminate \textit{M. tuberculosis} at low concentrations [14, 16, 20]. This discrepancy could result from the cell lines and species of mycobacteria used in different studies. We followed the toxicity guidelines and used primary cells [36, 38], with additional toxicity assays on NZX. For antimicrobial activity, this peptide was assayed against \textit{M. tuberculosis} H37Rv, but also three clinical isolates, of which one was resistant to the first-line antibiotics rifampicin and isoniazid. MIC values were similar for all species and strains investigated including the fast-growing \textit{M. smegmatis} and the bovine vaccine strain BCG.

Antimicrobial peptides are generally easily degradable, which could pose a treatment problem, but we demonstrated that NZX was not easily degraded by a range of proteases. In addition, NZX reduced the burden of \textit{M. tuberculosis} in the lungs of infected mice, further evidence that NZX is not readily degraded in these compartments. Interestingly, Grosset et al. investigated early bacterial activity of the first-line TB drugs [39], and showed that after two days of rifampin/isoniazid/pyrazinamide/ethambutol treatment the mean CFU counts were reduced by 0.25 log10 on day 2 and by 0.96 log10 on day 7. Applying the same calculations to our data, we observed a 0.45 log10 reduction of \textit{M. tuberculosis} in the lungs after five days of NZX-treatment compared with the untreated mice. No statistical difference was obtained between NZX and rifampicin treated mice in our study, but because this is a short-term treatment we cannot distinguish between NZX-mediated killing of bacteria and suppression of bacterial growth in vivo. However, these data suggest that NZX could be a useful addition to the current drug regimen used to treat TB.

During the different stages of infection \textit{M. tuberculosis} survives both intracellularly and extracellularly [40]. Susceptibility to first-line anti-TB drugs correlates poorly for \textit{M. tuberculosis} residing in macrophages compared to extracellular bacteria [41, 42]. In our study, NZX mediated a concentration-dependent reduction of intracellular \textit{M. tuberculosis} and we observed gold-labelled NZX inside alveolar macrophages from \textit{M. tuberculosis} infected mice. However, the antimycobacterial mechanism of NZX is yet unknown. NZ2114 and NZX contain the same cysteine target cell wall precursors in \textit{M. tuberculosis} in vitro [43]. We also observed gold-labelled NZX inside alveolar macrophages from \textit{M. tuberculosis} infected mice. However, the antmycobacterial mechanism of NZX is yet unknown. NZ2114 and NZX contain the same cysteine residues as plectasin suggesting structural similarity. These peptides also share histidine residues with plectasin. At physiological conditions, these histidines are largely unprotonated and uncharged with weak lytic properties [43]. However, NZ2114 and NZX could kill mycobacteria by other mechanisms, as plectasin was found to specifically inhibit mycobacteria residing in macrophages [44]. Taken together with the toxicity data, NZX appears to be able to target intracellular bacteria without lysing human cells. We also observed that NZX by reducing bacterial load in the lungs of infected mice, dampened leukocyte recruitment, which probably lead to the observed preserved tissue integrity. Whether NZX has immunomodulatory effect, in addition to its activity towards \textit{M. tuberculosis}, needs further investigation.

In this study, we present a novel AMP that effectively kills \textit{M. tuberculosis} in vitro and decreases the bacterial load in a murine TB infection model. The MIC and therapeutic dosage were comparable in their effectiveness to conventional TB-antibiotics, with no evidence of toxicity in our model systems. In addition, we found evidence that NZX has intracellular activity towards \textit{M. tuberculosis}, further supporting NZX as a possible future treatment candidate.

Conflicts of interest

All authors declare no conflict of interest.

Acknowledgements

GG conceived and designed the study. ET, NK, AR, SK, MM, MP, MD, MO and IG-M developed the methodology and acquired data. GG, ET, NK, ML and BR analysed and interpreted the data. GG, ET, BR, NK, AS, ML and ES wrote, reviewed, and/or revised the manuscript. NA provided administrative support. GG and ET supervised the study. All authors contributed significantly to the final version of the manuscript.

NK, IGM and BR thank the UK Medical Research Council for support in the MRC Centre for Molecular Bacteriology and Infection, Imperial College London. The research was funded by the Swedish Heart-Lung Foundation (20150733), Alfred Osterlunds Foundation, Royal Physiographic Society of Lund, Swedish Research Council and European Union’s Seventh Framework Programme (FP7/2007-2013) under grant agreement no 604182, FORMAMP-Innovative Nanoformulation of Antimicrobial Peptides to Treat Bacterial Infectious Diseases (http://ec.europa.eu.research). The funding sources had no involvement in this study.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.tube.2018.10.008.

References

[1] WHO. reportGlobal tuberculosis report 2017. http://wwwwho.int/tb/publications/global_report/en/. 2017;World Health Organization.

[2] Zamula A, Chakaya J, Centis R, D’Ambrosio L, Mwaba P, Bates M, et al. Tuberculosis treatment and management—an update on treatment regimens, trials, new drugs, and adjunct therapies. Lancet Respir Med 2015;3(3):220–34. https://doi.org/10.1016/S2213-2600(15)00063-6.

[3] Koul A, Arnould E, Lounis N, Guillomet J, Andries K. The challenge of new drug discovery for tuberculosis. Nature 2011;469(7311):483–90. https://doi.org/10.1038/nature09657.

[4] Adane K, Ameni G, Bekele S, Abebe M, Aseffa A. Prevalence and drug resistance profile of Mycobacterium tuberculosis isolated from pulmonary tuberculosis patients attending two public hospitals in East Gojam zone, northwest Ethiopia. BMC Public Health 2015;15:572. https://doi.org/10.1186/s12889-015-1933-9.

[5] Jassal M, Bishai WR. Extensively drug-resistant tuberculosis. Lancet Infect Dis 2009;9(1):19–30. https://doi.org/10.1016/S1473-3099(08)70260-3.

[6] Kieser JG, Baranowski C, Chao MC, Long JG, Sassetti CM, Waldor MB, et al. Peptidoglycan synthesis in Mycobacterium tuberculosis is organized into networks with varying drug susceptibility. Proc Natl Acad Sci U S A 2015;112(42):13087–92. https://doi.org/10.1073/pnas.1514135112.

[7] Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol 2003;3(9):710–20. https://doi.org/10.1038/nri1180.

[8] Hilchle AL, Wuerth K, Hancock RE. Immune modulation by multifaceted cationic host defense (antimicrobial) peptides. Nat Chem Biol 2013;9(12):761–8. https://doi.org/10.1038/nchembio.1393.

[9] Yeaman MR, Yount NX. Mechanisms of antimicrobial peptide action and resistance. Pharmacol Rev 2005;55(1):27–55. https://doi.org/10.1124/pr.55.1.2.

[10] Wimley WC. Describing the mechanism of antimicrobial peptide action with the interfacial activity model. ACS Chem Biol 2010;5(10):905–17. https://doi.org/10.1021/cb1001506.

[11] Linde CM, Hoffner SE, Refai E, Andersson M. In vitro activity of PR-39, a proline-arginine-rich peptide, against susceptible and multi-drug-resistant Mycobacterium tuberculosis. J Antimicrob Chemother 2001;47(5):575–80.

[12] Miyakawa Y, Ratnakar P, Rao AG, Costello ML, Mathieu-Costello O, Lehrer RI, et al. Peptidoglycan synthesis in Mycobacterium tuberculosis is organized into networks with varying drug susceptibility. Proc Natl Acad Sci U S A 2015;112(42):13087–92. https://doi.org/10.1073/pnas.1514135112.

[13] Jiang Z, Higgins MP, Whitehurst J, Kisich KO, Voskuil MI, Hodges RS. Anti-tubercular activity of synthetic cationic peptides. Antimicrob Agents Chemother 2007;51(2):621–6. https://doi.org/10.1128/AAC.00175-13.

[14] Ramon-Garcia S, Mikut R, Ng C, Ruden S, Volkmer R, Reischl M, et al. Targeting Mycobacterium tuberculosis and other microbial pathogens using improved synthetic antibacterial peptides. Antimicrob Agents Chemother 2013;57(5):2295–303. https://doi.org/10.1128/AAC.00175-13.

[15] Pearson CS, Kloo Z, Murray B, Tabe E, Gupta M, Kwak JH, et al. Combined bioinformatic and rational design approach to develop antimicrobial peptides against Mycobacterium tuberculosis. Antimicrob Agents Chemother.
E. Tenland et al.  
Tuberculosis 113 (2018) 231–238

[27] Martin CJ, Booty MG, Rosebrock TR, Nunes-Alves C, Desjardins DM, Keren I, et al. Efferocytosis is an innate antibacterial mechanism. Cell Host Microbe 2015;13(6):880–9. https://doi.org/10.1016/j.chom.2015.04.014.

[28] Sturegard E, Angeby KA, Werngren J, Jureen P, Kronvall G, Giske CG, et al. The cyclic peptide eumicin targeting ClpC1 is active against Mycobacterium tuberculosis in vivo. Antimicrob Agents Chemother 2015;59(11):5125–30. https://doi.org/10.1128/AAC.00453-11.

[29] Kalsum S, Braian C, Koeken V, Raffetseder J, Lindroth M, van Crevel R, et al. Activity of LL-37, CRAMP and antimicrobial peptide-derived compounds E2, E6 and CP26 against Mycobacterium tuberculosis. Int J Antimicrob Agents 2015;45(1):1–7. https://doi.org/10.1016/j.ijantimicag.2014.10.015.

[30] Raffetseder J, Pienaar E, Blomgran R, Eklund D, Patcha Brodin V, Andersson H, et al. Replication rates of Mycobacterium tuberculosis in human macrophages do not correlate with mycobacterial antibiotic susceptibility. PLoS One 2014;9(11):e101246. https://doi.org/10.1371/journal.pone.0101246.

[31] Marquina-Castillo B, Garcia-Garcia L, Ponce-de-Leon A, Jimenez-Corona ME, Bobadilla-Del Valle M, Cano-Arellano B, et al. Virulence, immunopathology and transmissibility of selected strains of Mycobacterium tuberculosis in a murine model. Immunology 2009;128(1):123–33. https://doi.org/10.1111/j.1365-2677.2008.03904.

[32] Stahl AL, Arvidsson I, Johansson KE, Chromek M, Rebetz J, Loos S, et al. A novel mechanism of bacterial toxin transfer within host blood cell-derived microvesicles. PLoS Pathog 2015;11(2):e1004619. https://doi.org/10.1371/journal.ppat.1004619.

[33] Festing MF, Altman DG. Guidelines for the design and statistical analysis of experiments using laboratory animals. ILAR J 2002;43(4):244–58.

[34] Morgan CJ. Use of proper statistical techniques for research studies with small samples. Am J Physiol Lung Cell Mol Physiol 2017;313(5):L873–7. https://doi.org/10.1152/ajplung.00238.2017.

[35] Abedinzadeh M, Gaeni M, Sardari S. Natural antimicrobial peptides against Mycobacterium tuberculosis. J Antimicrob Chemother 2015;70(5):1285–9. https://doi.org/10.1093/jac/dkw330.

[36] Assays for predicting acute toxicity. Application of modern toxicology approaches for predicting acute toxicity for chemical defense: National Academies Press (US); 2015.

[37] WHO. Treatment of tuberculosis - guidelines http://apps.who.int/iris/bitstream/10665/44165/1/9789241547833_eng.pdf [fourth ed.].

[38] Eklwall B, Silano V, Paganuzzi-Stammati A, Zucc F. Toxicity tests with mammalian cell cultures. Short-term toxicity tests for non-genotoxic effects: John Wiley & Sons Ltd; 1990. p. 75-93.

[39] Grosset J, Almeida D, Converse PJ, Tyagi S, Li SY, Ammerman NC, et al. Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide. Proc Natl Acad Sci U S A 2012;109(37):15001–5. https://doi.org/10.1073/pnas.1203636109.

[40] Warner DF, Mizrahi V. The survival kit of Mycobacterium tuberculosis. Nat Med 2010;328(5982):1168–72. https://doi.org/10.1126/science.1185723.

[41] Hartkoorn RC, Chandler B, Owen A, Ward SA, Bertel Squire S, Back DJ, et al. Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein. Tuberculosis (Edinb) 2007;87(3):248–55. https://doi.org/10.1016/j.tube.2006.12.001.

[42] Aljayyoussi G, Jenkins VA, Sharma R, Ardrey A, Donnellan S, Ward SA, et al. The cording phenotype of Mycobacterium tuberculosis induces the formation of extracellular traps in human macrophages. Front Cell Infect Microbiol 2017;7:278. https://doi.org/10.3389/fcimb.2017.00278.

[43] Schneider T, Kruse T, Wimmer R, Wiedemann I, Sass V, Pag U, et al. Plectasin, a fungal defensive, targets the bacterial cell wall precursor Lipo II. Science 2010;328(5982):1168–72. https://doi.org/10.1126/science.1185723.